Navigation Links
PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
Date:10/27/2008

tive and approved by regulatory authorities for commercial use in humans. Significant additional non-clinical animal studies, human clinical trials, and manufacturing development work remain to be done under this program. Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at http://www.pharmathene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
2. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
3. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
4. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
5. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
6. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
7. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
8. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
9. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
10. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
11. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014  Packaging Coordinators, Inc. (PCI) is pleased ... acquire Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma is ... the United Kingdom and operates ... and Tokyo , Japan. Penn Pharma ... and Commercial dosage form manufacturing, as well as Clinical ...
(Date:7/30/2014)...  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a ... expertise in opioid antagonists, announced today that it ... international research and development foundation. The ... initiatives, including those addressing health issues. Lightlake has ... of naloxone that could widely expand its availability ...
(Date:7/30/2014)... LAKE FOREST, Ill., July 30, 2014  Hospira, ... leading provider of injectable drugs and infusion technologies, ... June 30, 2014. Net sales for the quarter ... share were $0.72. (Adjusted* measures exclude specified items ... the attached schedules.) On a U.S. Generally Accepted ...
Breaking Medicine Technology:PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30
... NATICK, Mass., Nov. 25, 2011  RegenoCELL Therapeutics, Inc. (OTCBB: ... is pleased to announce that its wholly owned subsidiary ... with several potential new distributors.  It is anticipated that ... and begin purchasing cell processing services in the near ...
... Biopharmaceutical Company Moleac has announced the launch in France and ... supplement engineered to stimulate neuroplasticity and recovery. NurAiD II is ... operated by Moleac and a growing number of pharmacies across ... to support the restoration of neurological functions: ...
Cached Medicine Technology:Regenocell in Negotiations With Potential New Distributors to Increase Patient Flow 2Regenocell in Negotiations With Potential New Distributors to Increase Patient Flow 3Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement 2Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement 3
(Date:7/30/2014)... to artemisinin, the main drug to treat malaria, ... Plasmodium falciparum ( P. falciparum ) ... caused by a genetic mutation in the parasites. ... opposed to a standard three-day coursehas proved highly ... findings published today in the New England ...
(Date:7/30/2014)... Steven Reinberg HealthDay Reporter ... the United States, at least 2,000 Americans die from extreme ... Heat waves, heat stroke or sun stroke caused nearly ... and 2010, according to the U.S. Centers for Disease Control ... loss of body heat -- accounted for 63 percent of ...
(Date:7/30/2014)... News) -- It can happen in an instant: A small ... monitor and gets critically injured when the furniture tips over. ... look around their homes and imagine what could tip over, ... better than it becoming a reality," Dr. Alex Rosenau, president ... college news release. Between 2009 and 2011, roughly 43,000 ...
(Date:7/30/2014)... Hayward, CA (PRWEB) July 30, 2014 ... and accessories at the lowest prices on the internet ... Lightning Cables in two lengths and two colors. These ... performance standards. , The high quality SF Cable ... 8-pin connector with digital signal delivering faster charging and ...
(Date:7/30/2014)... York (PRWEB) July 30, 2014 The ... brain bleeding has filed a Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ... blood thinner, Bernstein Liebhard LLP reports. According to the ... the District of Vermont on July 25th, the decedent ... he suffered an irreversible brain bleed that ultimately led ...
Breaking Medicine News(10 mins):Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 3Health News:Tip-Over Furniture Can Kill Kids 2Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3
... News) -- More than half of U.S. jails didn,t receive ... H1N1 swine flu, a new study says. Jail and ... diseases. The steady stream of new arrivals can introduce new ... it easy for diseases to spread, researchers from the U.S. ...
... have been linked to depression, according to UT Southwestern ... Study. It is believed to be the largest such ... already are associated with a cavalcade of health woes ... published in Mayo Clinic Proceedings ...
... , THURSDAY, Jan. 5 (HealthDay News) -- Toddlers who miss ... later in life, a new study indicates. Researchers looked ... that depriving them of a single daily nap resulted in ... problem-solving abilities. "Many young children today are not getting ...
... clinical trial found that rilonacept, an inhibitor of ... flares that occur when initiating uric acid-lowering therapy. ... IL-1 targeted therapy in prevention of gout flaresshow ... serious infections or treatment-related serious adverse events reported. ...
... vector-borne disease in the United States, with the majority of ... since the agent of the disease, the spirochete Borrelia ... However, the number of Lyme disease cases have steadily increased. ... of the Journal of Medical Entomology called "What ...
... Reporter , WEDNESDAY, Jan. 4 (HealthDay News) -- A vaccine ... severe liver damage and even liver cancer, might be possible ... , There is currently no vaccine for hepatitis C, which ... HIV, the hepatitis C virus mutates easily and has always ...
Cached Medicine News:Health News:Many Jails Got No Flu Shots During H1N1 Outbreak: CDC 2Health News:Low vitamin D levels linked to depression, UT Southwestern psychiatrists report 2Health News:Missed Naps Could Put Toddlers at Risk for Mood Disorders 2Health News:Clinical trial demonstrates that rilonacept significantly reduces gout flares 2Health News:Clinical trial demonstrates that rilonacept significantly reduces gout flares 3Health News:How can Lyme disease be prevented and controlled? 2Health News:Novel Hepatitis C Vaccine Shows Some Early Promise 2Health News:Novel Hepatitis C Vaccine Shows Some Early Promise 3
Molteno3 Glaucoma Drainage Device incorporates the latest advances from Professor Moltenos glaucoma research. It has been extensively tested since early 2004 and gives even better control of intraocu...
... 2.0 is a reagent and probe system ... The high throughput plate based system is ... provides a unique approach for RNA detection ... using branched DNA (bDNA) technology. Branched DNA ...
Cormet Hip Resurfacing is a conservative treatment for the young, active, high demand patient group which conserves femoral bone, provides anatomical bone loading, eliminates polyethylene and is desi...
QC 123 is an assayed quality control material for blood gas instrumentation. It is available in three (3) levels for monitoring analyzer performance at varying points within the clinical range....
Medicine Products: